Advanced searches left 3/3

Metastatic Breast Cancer - DOAJ

Summarized by Plex Scholar
Last Updated: 23 April 2022

* If you want to update the article please login/register

Stress in Metastatic Breast Cancer: To the Bone and Beyond

Breast cancer remains as one of the most common cancers in industrialized countries. Although the overall survival rate is high, BRCA cells' dissemination of BRCA cells to distant organs correlates with a significantly poor prognosis. Over the past decade, new correlations between stress and BRCA metastases have been identified. Since bone is a common target site for BRCA metastases, greater attention will be given to the role of 2- and -adrenergic signalling in BRCA bone tropism and the occurrence of osteolytic lesions.

Source link: https://doi.org/10.3390/cancers14081881


Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions

In several solid tumors, including breast cancer, the role of radiotherapy and immunotherapy with immune checkpoint inhibitors is of growing importance. There is growing evidence that the host's immune system plays a significant role in breast cancer treatment and prognosis. Several pre-clinical and clinical studies have reported on the 'abscopal effect, — the regression of distant untreated tumor sites, mediated by an immunological reaction after ionizing radiation to a targeted tumour site. Stereotactic Ablative Body Radiotherapy (BRT) is a non-invasive method used to enhance various immune responses with an ablative tumoricidal dose relative to conventional radiotherapy. Following SABR, there is evidence of systemic immune stimulation in patients with elevated PD1 levels on CD8+ and CD4+ T cells. Metastatic triple-negative disease, a rare immunogenic subtype of breast cancer with poor prognosis, is a common cause of breast cancer with poor prognosis.

Source link: https://doi.org/10.3390/biomedicines10040821


Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells

Methods 170 kinase inhibitors were applied to MCF-7 cells either with adaptative or genetic resistance to ET drugs, and both ER levels and cell proliferation were measured. Interestingly, women carrying luminal A BC have an extended RFS when expressing low CHK1 levels. According to the ATR:CHK1 pathway, CHK1 and ER activation in ER-positive BC cell lines are linked, while ER-positive BC cell lines control ER stability and cell proliferation in luminal A BC cells. DNA replication stress rather than DNA damage caused by ATR:CHK1 pathway inhibition, rather than DNA damage caused by ATR:CHK1 pathway inhibition, is a prerequisite for ER degradation. CHK1 inhibitors in clinical trials for primary and MBC stem cell proliferation, and drugs approved for clinical treatment of primary and MBC inhibit cell proliferation, and chemotherapy for primary and MBC have synergic consequences with CHK1 inhibitors in preventing cell proliferation of cells modeling primary and MBC.

Source link: https://doi.org/10.1186/s13046-022-02360-y


Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer

paraphrasedoutput:Abstract: Ixabepilone, a novel microtubule stabilizing agent that was recently approved for the treatment of metastatic breast cancer, according to Marta Vallee Cobham, Diana DonovanWeill Cornell Breast Center, Cornell University/New York-Presbyterian Hospital, New York, NY, USA. This article explores the implications for ixabepilone administration and adverse event management in PubMed, published abstracts from the American Society of Clinical Oncology annual meetings, and the manufacturer's prescribing data for ixabepilone. Oncology nurses will see more patients receiving ixabepilone therapy as the ixabepilone formula improves in earlier lines of breast cancer therapy and in other solid tumors.

Source link: https://doaj.org/article/e265c58addee4c2c9e0b993df3a1a3c7


A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report

Abstract Background: Many cancers have been attributed to paraneoplastic syndromes. Presentation of a case We present a case where a patient presenting with papillitis, myositis, and sensory peripheral neuropathy 18 months before a diagnosis of metastatic oestrogen receptor positive breast cancer was revealed. Conclusions This case is an example of breast cancer that has paraneoplastic signs. Patients with unusual medical signs in women with no apparent cause were unable to establish the cause of symptoms in this patient, illustrating the importance for doctors to keep a high degree of suspicion for paraneoplastic syndromes in women with unusual medical signs with no apparent cause.

Source link: https://doi.org/10.1186/1477-7819-6-132


Association of carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA 15-3) with socio-demographic factors and metastases site in women with metastatic breast cancer in Albania

Aim: Our aim was to determine the relationship between carcinoembryonic antigen and cancer antigen 15-3 with socioeconomic status and metastases site in women with metastatic breast cancer in Albania's post-communist Albania. Methods: A case-series research was conducted in Tirana, Albania's capital, between January 2010 and September 2017, involving 110 female patients diagnosed with breast cancer with metastases at the University Hospital Centre "Mother Teresa" in Tirana, the Albanian capital, during the period January 2010 – September 2017. Conclusion: This report provides valuable insight into selected correlates of CEA and CA15-3 in Albanian female patients with metastatic breast cancer. Oncologists and other health professionals in Albania, as well as policymakers and policymakers, should be aware of the prevalence and risk factors of breast cancer among women in this transitional society.

Source link: https://doi.org/10.4119/seejph-1864


Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?

Circulating tumor cell count has prognostic value in metastatic breast cancer, but the CTC's predictive value is uncertain. Improved enrichment techniques are now enabling molecular characterization of single CTCs, whereby molecular markers on single CTCs can be used to obtain a real-time measurement of tumor biomarker status from a blood test or "liquid biopsy," possibly avoiding the need for a more costly tissue biopsy. The clinical relevance of biomarkers, including the increase of HER2 on CTC for HER2-negative primary breast cancer, is uncertain, in addition to the need to define and confirm the most accurate and reproducible method for CTC molecular research.

Source link: https://doi.org/10.3390/cancers6020684


Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era

Purpose This paper investigated the use and effects of brain radiotherapy for brain metastases from breast cancer among the population-based use and results of brain radiotherapy, with a focus on repeat BRT in the trastuzumab period. Methods and materials From a provincial database, women with breast cancer diagnosed from 2000-2007 and treated with BRT were retrospectively identified. Results A total of 441 women with breast cancer BM were found. The median age was 55 years and 40% had an epidermal growth factor receptor 2 positive disease. Conclusion Compared to initial BRT, the number of cases with HER2 positive disease was higher at repeat BRT than in initial BRT.

Source link: https://doi.org/10.1186/1748-717X-6-181


Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies

Abstract Background: In peripheral blood of metastatic breast cancer patients, circulating tumor cells are detectable. We review a new CTC separation technique based on a combination of anti-EpCAM- and anti-cytokeratin magnetic cell separation in this paper with the intention of improving CTC detection with low target antigen densities. Methods The method's were based on blood samples of healthy donors spiked with the breast cancer cell line HCC1937 to determine the accuracy and precision of the procedure. To determine the prognostic value on overall survival, the prognostic value was determined in 59 patients with MBC. p Conclusions We find that our CTC detection system is effective and reliable, with a cut-off point between risk groups. Our results show that a more refined distinction between patients with different CTC levels is appropriate.

Source link: https://doi.org/10.1186/1471-2407-12-206

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions